Cost-Benefit Analysis of Hepatitis-B Vaccination: A Computerized Decision Model for Spain

Jönsson, Bengt; Horisberger, Bruno; Bruguera, Miguel; Matter, Lukas (1991). Cost-Benefit Analysis of Hepatitis-B Vaccination: A Computerized Decision Model for Spain. International journal of technology assessment in health care, 7(3), pp. 379-402. Cambridge University Press 10.1017/S0266462300005754

Preview

Text S0266462300005754.pdf - Published Version Available under License Publisher holds Copyright. Download (1MB) | Preview

The availability and efficacy of recombinant deoxyribonucleic acid yeast-derived hepatitis-B vaccine, at a price much lower than the previously available plasma-derived hepatitis-B vaccines against hepatitis-B virus infections, motivate a new cost-benefit analysis of hepatitis-B vaccination. Spanish data were used to calculate direct and indirect costs of hepatitis-B infection and the costs and benefits of different vaccination strategies in defined risk groups of the Spanish population. A vaccination program will reduce direct expenditures for hepatitis B if the attack rate in the target population is higher than 4.9%. If indirect costs are included, the threshold for cost saving is reduced to 0.9%. The results are sensitive to the price of the vaccine, the duration of protection, assumptions about consequences for quality of life, and to indirect costs.

Interest & Impact

Downloads

165 since deposited on 03 Aug 2020
22 in the past 12 months

Citations

5 Citations in Web of Science ®
6 Citations in Scopus

Search

in Google Scholar™

Services

Actions (login required)

Edit item

Actions (login required)

Edit item